基于网络药理学研究小檗碱治疗结肠炎的机制

doi:10.3760/cma.j.cn441417-20241125-16011

国际医药卫生导报 ›› 2025, Vol. 31 ›› Issue (16): 2693-2698.DOI: 10.3760/cma.j.cn441417-20241125-16011

基于网络药理学研究小檗碱治疗结肠炎的机制

薛雪峰¹ 刘文栋¹ 王捷虹²

¹西安中医脑病医院重症医学科，西安 710038；²陕西中医药大学附属医院消化一科，咸阳 712000

收稿日期:2024-11-25 出版日期:2025-08-15 发布日期:2025-08-28
通讯作者: 刘文栋，Email：523260239@qq.com
基金资助:
陕西省中医药管理局重点研究室项目（陕中医药发【2018】32号）

Mechanism of berberine in treating colitis based on network pharmacology

Xue Xuefeng¹, Liu Wendong¹, Wang Jiehong²

¹Department of Critical Care Medicine, Xi'an Traditional Chinese Medicine Brain Disease Hospital, Xi'an 710038, China; ²First Department of Digestive Diseases, Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang 7120000, China

Received:2024-11-25 Online:2025-08-15 Published:2025-08-28
Contact: Liu Wendong, Email: 523260239@qq.com
Supported by:
Project Supported by Key Studio of Shaanxi Bureau of Traditional Chinese Medicine (No.201832)

摘要/Abstract

摘要：

目的　基于网络药理学及实验验证探究小檗碱对结肠炎的保护作用及机制。方法　网络药理学分析的数据检索时间为2023年6月。结合PharmMapper、Swiss Target Prediction、Genecards等数据库筛选小檗碱中含有的有效成分及作用靶点，利用Cytoscape 3.9.1软件构建“疾病-靶点-化合物”网络。结合STRING数据库构建蛋白相互作用（protein-protein interaction，PPI）网络筛选核心靶点；使用David数据库对共同靶点进行基因本体功能（gene ontology，GO）与基因组百科全书（Kyoto Encyclopedia of Genes and Genomes，KEGG）通路富集分析，获取潜在信号通路，并对结果进行可视化。建立脂多糖（lipopolysaccharide，LPS）诱导的结肠腺癌细胞Caco-2细胞模型，探讨小檗碱治疗结肠炎的效果及作用机制。结果　通过数据库整理分析筛选出药物和疾病相关交集靶点共86个，主要核心靶点为JAK3、VEGFR2、ANXA5、NQO1；GO和KEGG富集分析结果表明，小檗碱主要是通过JAK3/STAT1信号通路发挥治疗结肠炎的作用。细胞实验结果显示，小檗碱可以抑制JAK3/STAT1信号通路，抑制LPS诱导的Caco-2细胞中白细胞介素-1β（interleukin-1β，IL-1β）的表达，减轻炎症反应。结论　小檗碱可以通过抑制JAK3-STAT1信号通路减少LPS诱导Caco-2细胞的炎症反应，增强肠道屏障功能，达到治疗结肠炎的作用。

关键词:

结肠炎, 小檗碱, 网络药理学, 炎症, JAK3-STAT1

Abstract:

Objective　To explore the protective effect and mechanism of berberine on colitis based on network pharmacology and experimental verification. Methods　The data retrieval time for the network pharmacology analysis was June 2023. The databases, such as PharmMapper, SwissTarget Prediction, and Genecards, were used to screen the active ingredients and targets in berberine, and a "disease target compound" network was constructed by the Cytoscape 3.9.1 software. A protein-protein interaction (PPI) network was constructed based on the STRING database to screen the core targets. The gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses on common targets were performed using the David database to obtain the potential signaling pathways and to visualize the results. A lipopolysaccharide (LPS) -induced Caco-2 cell model of colon adenocarcinoma cells was established to investigate the efficacy and mechanism of berberine in treating colitis. Results　Through database analysis and sorting, a total of 86 intersecting targets related to drugs and diseases were identified, and the main core targets were JAK3, VEGFR2, ANXA5, and NQO1. The GO and KEGG enrichment analyses results indicated that berberine mainly exerted its therapeutic effect on colitis through the JAK3/STAT1 signaling pathway. Cell experiments have shown that berberine can inhibit the JAK3/STAT1 signaling pathway, suppress the levels of interleukin-1β in Caco-2 cells induced by LPS, and alleviate inflammatory responses. Conclusions　Berberine can reduce LPS-induced inflammatory response in Caco-2 cells inhibiting the JAK3-STAT1 singnaling pathway, enhance intestinal barrier function, and achieve therapeutic effects on colitis.

Key words:

Colitis, Berberine, Network pharmacology, Inflammation, JAK3-STAT1

薛雪峰刘文栋王捷虹.

基于网络药理学研究小檗碱治疗结肠炎的机制 [J]. 国际医药卫生导报, 2025, 31(16): 2693-2698.

Xue Xuefeng, Liu Wendong, Wang Jiehong.

Mechanism of berberine in treating colitis based on network pharmacology [J]. International Medicine and Health Guidance News, 2025, 31(16): 2693-2698.

参考文献

[1] 石亚军,仝甲钊,何玉婷,等. 专人健康教育联合辨证膳食干预对溃疡性结肠炎患者的影响[J]. 国际医药卫生导报, 2020, 26(6):788-791. DOI:10.3760/cma.j.issn.1007-1245.2020.06.014.
[2] Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis [J]. Lancet, 2017, 389(10080):1756-1770. DOI: 10.1016/S0140-6736(16)32126-2.
[3] Yao D, Dong M, Dai C, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects[J]. Inflamm Bowel Dis. 2019, 25(10):1595-1602. DOI:10.1093/ibd/izz149.
[4] 苏晓兰,王琳,张涛,等.清热化湿调枢方对溃疡性结肠炎小鼠肠道黏膜屏障功能的影响[J].中国实验方剂学杂志,2022,28(22):68-75.DOI:10.13422/j.cnki.syfjx.20222294.
[5] 缪延栋,赵雪寒,张怡明,等. 免疫检查点抑制剂治疗恶性肿瘤所致免疫相关不良反应预测标志物的研究进展[J]. 中华肿瘤防治杂志, 2024, 31(6):383-390. DOI:10.16073/j.cnki.cjcpt.2024.06.11.
[6] Rogler G. Chronic ulcerative colitis and colorectal cancer[J]. Cancer Lett, 2014, 345(2):235-241. DOI:10.1016/j.canlet.2013.07.032.
[7] Hu X, Li J, Fu M, et al. The JAK/STAT signaling pathway: from bench to clinic[J]. Signal Transduct Target Ther, 2021, 6(1):402. DOI:10.1038/s41392-021-00791-1.
[8] Banerjee S, Biehl A, Gadina M, et al. JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects[J]. Drugs, 2017, 77(5):521-546. DOI:10.1007/s40265-017-0701-9.
[9] Dodington DW, Desai HR, Woo M. JAK/STAT - emerging players in metabolism[J]. Trends Endocrinol Metab, 2018, 29(1):55-65. DOI:10.1016/j.tem.2017.11.001.
[10] Luo Y, Alexander M, Gadina M, et al. JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition[J]. J Allergy Clin Immunol, 2021, 148(4): 911-925. DOI:10.1016/j.jaci.2021.08.004.
[11] Yeung YT, Aziz F, Guerrero-Castilla A, et al. Signaling pathways in inflammation and anti-inflammatory therapies[J]. Curr Pharm Des, 2018, 24(14): 1449-1484. DOI:10.2174/1381612824666180327165604.
[12] Liu C, Hua H, Zhu H, et al. Aloe polysaccharides ameliorate acute colitis in mice via Nrf2/HO-1 signaling pathway and short-chain fatty acids metabolism[J]. Int J Biol Macromol, 2021, 185: 804-812. DOI: 10.1016/j.ijbiomac.2021.07.007.
[13] Wang X, Gao Y, Wang L, et al. Troxerutin improves dextran sulfate sodium-induced ulcerative colitis in mice[J]. J Agric Food Chem, 2021, 69(9): 2729-2744. DOI:10.1021/acs.jafc.0c06755.
[14] 王贺然,桑力轩,郑长清. 小分子药物治疗炎症性肠病的疗效和临床应用[J]. 中华消化杂志, 2024, 44(1):22-27. DOI: 10.3760/cma.j.cn311367-20231030-00142.
[15] Cai J, Liu J, Fan P, et al. Dioscin prevents DSS-induced colitis in mice with enhancing intestinal barrier function and reducing colon inflammation [J]. Int Immunopharmacol, 2021, 99: 108015. DOI:10.1016/j.intimp.2021.108015.
[16] 陈琴,张志云,石西南,等. 基于IL-6/STAT3信号通路探讨miR-34a-5p过表达对溃疡性结肠炎的影响及小檗碱的干预作用[J]. 山东医药, 2024, 64(1):1-5. DOI: 10.3969/j.issn.1002-266X.2024.01.001.
[17] Ma SR, Tong Q, Lin Y, et al. Berberine treats atherosclerosis via a vitamine-like effect down-regulating Choline-TMA-TMAO production pathway in gut microbiota[J]. Signal Transduct Target Ther, 2022, 7(1): 207. DOI:10.1038/s41392-022-01027-6.
[18] Yang T, Wang R, Liu H, et al. Berberine regulates macrophage polarization through IL-4-STAT6 signaling pathway in Helicobacter pylori-induced chronic atrophic gastritis[J]. Life Sci, 2021, 266:118903. DOI: 10.1016/j.lfs.2020.118903.
[19] Habtemariam S. Berberine pharmacology and the gut microbiota: a hidden therapeutic link[J]. Pharmacol Res, 2020, 155:104722. DOI:10.1016/j.phrs.2020.104722.
[20] Cui H, Cai Y, Wang L, et al. Berberine regulates Treg/Th17 balance to treat ulcerative colitis through modulating the gut microbiota in the colon[J]. Front Pharmacol, 2018, 9: 571. DOI: 10.3389/fphar.2018.00571.
[21] Li H, Fan C, Lu H, et al. Protective role of berberine on ulcerative colitis through modulating enteric glial cells-intestinal epithelial cells-immune cells interactions[J]. Acta Pharm Sin B, 2020, 10(3):447-461. DOI:10.1016/j.apsb.2019.08.006.
[22] 王新,唐丽,杨造鹏,等. 小檗碱对DSS结肠炎小鼠发挥保护作用的实验观察[J]. 中成药, 2016, 38(5): 1132-1135. DOI: 10.3969/j.issn.1001-1528.2016.05.035.
[23] Sabzevary-Ghahfarokhi M, Soltani A, Luzza F, et al. The protective effects of resveratrol on ulcerative colitis via changing the profile of Nrf2 and IL-1β protein[J]. Mol Biol Rep, 2020, 47(9):6941-6947. DOI:10.1007/s11033-020-05753-4.
[24] Cordes F, Foell D, Ding JN, et al. Differential regulation of JAK/STAT-signaling in patients with ulcerative colitis and Crohn's disease[J]. World J Gastroenterol, 2020, 26(28):4055-4075. DOI:10.3748/wjg.v26.i28.4055.

基于网络药理学研究小檗碱治疗结肠炎的机制

Mechanism of berberine in treating colitis based on network pharmacology

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	陈蕾马艳梅张敏. 自拟银翘清解汤联合强脉冲光治疗玫瑰痤疮患者的效果研究 [J]. 国际医药卫生导报, 2025, 31(8): 1283-1287.
[2]	王亚桃李锋饶周舟. 妊娠肝内胆汁淤积症患者SIRI、pro-ADM、MDH1水平与妊娠结局的关系 [J]. 国际医药卫生导报, 2025, 31(8): 1287-1291.
[3]	刘雪妮惠容容　邓庆. 多普勒超声与炎症指标诊断T2DM患者下肢血管病变的价值 [J]. 国际医药卫生导报, 2025, 31(8): 1337-1342.
[4]	杨宝华董博苟威. 小针刀松解联合中药热敷治疗粘连性肩周炎的临床疗效与安全性观察 [J]. 国际医药卫生导报, 2025, 31(7): 1103-1107.
[5]	史汉金马惠旋王远平. 基于网络药理学和分子对接技术探讨心可舒治疗冠心病的作用机制 [J]. 国际医药卫生导报, 2025, 31(7): 1140-1148.
[6]	栗玮王岩赵伟. Klotho通过抑制NLRP3炎症小体对自发性高血压大鼠肾损伤的影响 [J]. 国际医药卫生导报, 2025, 31(7): 1149-1156.
[7]	潘文昕姜伟炜. 结肠镜检查时机对缺血性结肠炎患者预后影响的研究进展 [J]. 国际医药卫生导报, 2025, 31(6): 914-917.
[8]	权皎洁王小玲陈惠娟. 高通量血液透析联合血液透析滤过治疗终末期肾病的效果 [J]. 国际医药卫生导报, 2025, 31(5): 729-733.
[9]	李楠孙双春延育强张勤. 罗哌卡因连续胸椎旁神经阻滞对胸腔镜肺叶切除术患者的影响 [J]. 国际医药卫生导报, 2025, 31(5): 801-805.
[10]	韩昭张薇张旭龙. 醒脑开窍针联合加味涤痰汤治疗风痰瘀阻证脑卒中后失语症患者的疗效 [J]. 国际医药卫生导报, 2025, 31(5): 833-838.
[11]	巨岩史波　杨德民. 血管内介入栓塞术对脑动脉瘤患者血清炎症因子、氧化应激及脑血管状态的影响 [J]. 国际医药卫生导报, 2025, 31(4): 568-572.
[12]	鲁小庆郭亚平边静赵东艳景煊峰赵亚峰. 加味补阳还五汤联合西药治疗特发性膜性肾病患者的效果 [J]. 国际医药卫生导报, 2025, 31(4): 573-577.
[13]	张国腾王毅周沛邱世诚周剑鹏. 富血小板血浆对白细胞介素-1β诱导大鼠髓核细胞凋亡的影响 [J]. 国际医药卫生导报, 2025, 31(4): 591-596.
[14]	张世洁康云慧张燕子张凯歌汪靖园. 常规炎症因子及新型炎症标志物对糖尿病肾病尿毒症患者尿路感染的预测价值 [J]. 国际医药卫生导报, 2025, 31(4): 658-663.
[15]	张继洋蒋鹏李鹏飞宋宇轩杨延辉. 不同浓度富血小板血浆联合关节股四头肌训练在膝关节骨性关节炎软骨修复中的应用效果 [J]. 国际医药卫生导报, 2025, 31(3): 449-453.